Baudax Bio IncNASDAQ:BXRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5399
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5401/ 15
- Ask / Lots0.5474/ 5
- Open / Previous Close0.0000 / 0.5399
- Day Range---
- 52 Week Range
- Volume1,366
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | BXRX |
|---|
Oct 5, 2021
Baudax Bio to Present at the NobleCon Pain Management Investor Forum
Oct 1, 2021
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Baudax Bio Inc | 45.6M | -1.4x | --- |
Midatech Pharma PLC | 34.5M | -2.0x | --- |
Marizyme Inc | 47.0M | -4.4x | --- |
Forward Pharma A/S | 46.3M | -8.7x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 46.3M | -14.2x | --- |
Inhibikase Therapeutics Inc | 48.3M | -2.7x | --- |
Company Information
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The Company is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.
Contact Information
- Headquarters
- 490 Lapp RdMALVERN, PA, United States 19355-1212
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Alfred Altomari
- President, Chief Executive Officer, Director
- Geraldine Henwood
- Chief Financial Officer
- Richard Casten
- Independent Director
- William Ashton
- Independent Director
- Arnold Baskies
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.6M |
|---|---|
Revenue (TTM) | $543.0K |
Shares Outstanding | 84.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.40 |
Book Value | $-0.30 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 83.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,787.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
